A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naive Subjects

Trial Profile

A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naive Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PREZENT
  • Most Recent Events

    • 27 Oct 2017 Results of a substudy assessing the cerebrospinal fluid concentrations, efficacy and neurocognitive effects of darunavir/cobicistat and Rilpivirine, presented at the 16th European AIDS Conference.
    • 27 Oct 2017 Status changed to completed.
    • 27 Oct 2017 Results presented at the 16th European AIDS Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top